FDG PET-CT Scan
Whole-body metabolic imaging that helps us stage and monitor aggressive bladder, kidney, testicular, and metastatic prostate cancers when precise answers matter.
Educational content only. All imaging orders are personalized after review by your Advanced Urology physician.
What Is an FDG PET-CT?
An FDG PET-CT scan uses a radioactive glucose analog — fluorodeoxyglucose (FDG) — to highlight cells with accelerated metabolism. Cancer cells consume glucose rapidly, so they often light up brightly on PET images. We combine that functional data with a CT scan to pinpoint exactly where those hot spots are located.
This technology is especially helpful for aggressive or metastatic urologic cancers where conventional imaging may miss subtle disease.
When We Recommend FDG PET-CT
Common Urologic Indications
- High-grade bladder cancer staging and surveillance.
- Renal cell carcinoma with suspected metastatic spread.
- Testicular cancer restaging when tumor markers rise.
- PSMA-negative prostate cancers or neuroendocrine variants.
- Clarifying indeterminate lesions seen on CT or MRI.
What FDG PET-CT Adds
- Detects hidden nodal, bone, or visceral metastases.
- Assesses treatment response after immunotherapy or chemotherapy.
- Helps distinguish scar tissue from active tumor.
- Guides biopsy to the most metabolically active site.
How the Scan Works
Tracer Uptake
You receive an IV injection of FDG. After about 60 minutes of quiet rest (no speaking, minimal movement), the tracer distributes through your body. Cancer cells trap the glucose analogue, making them glow on the PET images.
PET + CT Fusion
The scanner first acquires a low-dose CT for anatomy, followed by PET imaging from skull base to mid-thigh (or head-to-toe when needed). We fuse the datasets to create color overlays that show metabolic activity against high-resolution anatomy.
FDG vs PSMA PET-CT
| Feature | FDG PET-CT | PSMA PET-CT |
|---|---|---|
| Tracer Target | Glucose uptake (cell metabolism) | Prostate-specific membrane antigen receptors |
| Best For | High-grade bladder, kidney, testicular, sarcomatoid, and aggressive prostate variants | Most prostate cancers, especially biochemical recurrence at low PSA |
| Limitations | Physiologic uptake in brain, bowel, urinary tract can obscure lesions | Some aggressive variants lose PSMA expression |
| Insurance Coverage | Broad coverage for oncologic indications | Rapidly expanding coverage; prior auth required |
Preparing for Your Scan
24 Hours Before
- Follow a low-carbohydrate, high-protein diet; avoid sugary drinks and alcohol.
- Avoid strenuous exercise to prevent muscle uptake.
- Hydrate well with water; stop eating 6 hours before arrival.
Day of the Scan
- Take routine medications unless instructed otherwise (diabetics receive special guidance).
- Wear warm, comfortable clothing without metal.
- Bring recent labs, imaging, and a list of medications.
- Plan to be at the imaging center for about 2.5 hours.
What to Expect
During Your Visit
- Check in, review your clinical history, and place an IV line.
- Receive the FDG injection, then relax in a quiet room for uptake.
- Empty your bladder before imaging to reduce pelvic artifact.
- Lie still on the scanner table for 20–30 minutes as PET-CT images are acquired.
After the Scan
- Drink plenty of fluids to flush tracer through the kidneys and bladder.
- You can resume normal activities immediately.
- Avoid close contact with pregnant individuals or infants for 6 hours.
- Results are interpreted the same day and forwarded to your physician.
Interpreting the Results
Multidisciplinary Review
Advanced Urology physicians partner with fellowship-trained nuclear radiologists. We integrate the PET-CT findings with pathology, tumor markers, genomic testing, and prior imaging to tailor your care plan.
- Localized uptake may prompt targeted surgery or radiation.
- Oligometastatic disease opens options for stereotactic radiation or metastasis-directed therapy.
- Widespread uptake guides systemic therapy, clinical trials, or palliative strategies.
Potential Pitfalls
- Inflammation, recent surgery, or infection can produce false positives.
- Small lesions under 5 mm may not accumulate enough tracer.
- High blood sugar competes with FDG; we reschedule if glucose is uncontrolled.
Why Advanced Urology
Frequently Asked Questions
Is FDG PET-CT safe?
Yes. The tracer leaves your body quickly, and the overall radiation dose is comparable to a diagnostic CT. Side effects are rare.
Will insurance cover the scan?
Most insurers, including Medicare, cover FDG PET-CT for approved oncologic indications. Our team secures prior authorization before scheduling.
How quickly will I get results?
We typically review and communicate results within one business day, often sooner for urgent cases.
Can FDG PET-CT replace biopsy?
It guides biopsy sites but rarely replaces tissue diagnosis. We use it alongside pathology to confirm the exact cancer type.
Next Steps
If you have a new cancer diagnosis or need clarification after treatment, our imaging specialists partner with your urologist to determine whether FDG PET-CT is the right next step.